WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007017249) DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/017249    International Application No.:    PCT/EP2006/007840
Publication Date: 15.02.2007 International Filing Date: 08.08.2006
IPC:
A61K 9/14 (2006.01)
Applicants: ABBOTT GMBH & CO. KG [DE/DE]; Max-Planck-Ring 2, 65205 Wiesbaden (DE) (For All Designated States Except US).
BERNDL, Gunther [DE/DE]; (DE) (For US Only).
DEGENHARDT, Matthias [DE/DE]; (DE) (For US Only).
MÄGERLEIN, Markus [DE/DE]; (DE) (For US Only)
Inventors: BERNDL, Gunther; (DE).
DEGENHARDT, Matthias; (DE).
MÄGERLEIN, Markus; (DE)
Agent: REITSTÖTTER-KINZEBACH; Reitstötter, Kinzebach & Partner (GbR), Sternwartstrasse 4, 81679 München (DE)
Priority Data:
60/595,818 08.08.2005 US
Title (EN) DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY
(FR) FORMES POSOLOGIQUES À BIODISPONIBILITÉ ACCRUE
Abstract: front page image
(EN)A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35 > &Dgr;Htr (1) (wherein AHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product is used for the manufacture of a dosage form having improved bioavailability of said one or more active ingredients by oral administration to a patient in need thereof.
(FR)L'invention concerne un produit à dispersion solide dont le volume effectif compte un ou plusieurs ingrédients actifs ainsi que une ou plusieurs méthylcelluloses hydroxypropyliques, en conformité avec la Formule 0,35 > DHtr (1) (où AHtr représente l'endotherme (J/g) qui accompagne une transition à environ 240 °C). Le produit à dispersion solide est employé dans la production d'une formule posologique à la biodisponibilité améliorée de ce ou ces ingrédients actifs administrés par voie orale au patient concerné.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)